Nikhil Wagle

Nikhil Wagle

Harvard University

H-index: 56

North America-United States

About Nikhil Wagle

Nikhil Wagle, With an exceptional h-index of 56 and a recent h-index of 46 (since 2020), a distinguished researcher at Harvard University, specializes in the field of cancer genomics, therapeutic resistance, personalized cancer medicine.

His recent articles reflect a diverse array of research interests and contributions to the field:

Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers

Abstract PO4-16-09: Enhancing Research on Inflammatory Breast Cancer through Count Me In: Assessing the Accuracy of Self-Reported Diagnoses

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer

MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone …

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments

Patient-partnered research enables germline characterization of angiosarcoma predisposition genes

Nikhil Wagle Information

University

Position

Dana-Farber Cancer Institute, Harvard Medical School / Broad Institute of Harvard and MIT

Citations(all)

19628

Citations(since 2020)

11365

Cited By

12364

hIndex(all)

56

hIndex(since 2020)

46

i10Index(all)

95

i10Index(since 2020)

89

Email

University Profile Page

Google Scholar

Nikhil Wagle Skills & Research Interests

cancer genomics

therapeutic resistance

personalized cancer medicine

Top articles of Nikhil Wagle

Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers

Cancer Research

2024/5/2

Abstract PO4-16-09: Enhancing Research on Inflammatory Breast Cancer through Count Me In: Assessing the Accuracy of Self-Reported Diagnoses

Cancer Research

2024/5/2

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer

Cancer Research

2023/4/4

MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors

2023/10/17

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone …

Journal of Clinical Oncology

2024/3/21

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Nature Communications

2024/3/19

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments

Nature Cell Biology

2024/3/5

Patient-partnered research enables germline characterization of angiosarcoma predisposition genes

Cancer Research

2023/4/4

Eliezer Van Allen
Eliezer Van Allen

H-Index: 66

Nikhil Wagle
Nikhil Wagle

H-Index: 42

Systematic functional and phenotypic characterization of HER2 missense mutants and their impact in ER+ metastatic breast cancer

Cancer Research

2023/4/4

The Osteosarcoma and leiomyosarcoma count me in projects of the cancer moonshot funded PE-CGS network directly engage patient participants in genomics research

Cancer Research

2023/4/4

Priorities to promote participant engagement in the participant engagement and cancer genome sequencing (PE-CGS) network

Cancer Epidemiology, Biomarkers & Prevention

2023/4/3

Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations

Clinical Cancer Research

2023/4/3

Nikhil Wagle
Nikhil Wagle

H-Index: 42

Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer

Cancer Research

2023/3/1

John Navarro
John Navarro

H-Index: 3

Nikhil Wagle
Nikhil Wagle

H-Index: 42

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Cancer Research

2023/3/1

Abstract Gs3-06: Gs3-06 Palbociclib after Cdk4/6I and endocrine therapy (PACE): A randomized phase II study of Fulvestrant, Palbociclib, and Avelumab for endocrine pre-treated …

Cancer Research

2023/3/1

Abstract P3-02-02: Real-World Time-to-Treatment Discontinuation in Hormone-Receptor-Positive Metastatic Breast Cancer Patients following CDK4/6 Inhibitor Treatment, Based on …

Cancer Research

2023/3/1

Nikhil Wagle
Nikhil Wagle

H-Index: 42

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

The Lancet Oncology

2023/3/1

Genomic Predictors of Leptomeningeal Disease Development among Patients with Brain Metastases

International Journal of Radiation Oncology, Biology, Physics

2023/10/1

A genomic score to predict local control among patients with brain metastases managed with radiation

Neuro-Oncology

2023/10/1

The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries

medRxiv

2023

See List of Professors in Nikhil Wagle University(Harvard University)